Reaction
Weight Loss Poor reporting signals
As of the last recalculation, Weight Loss Poor appears in 4,507 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is LIRAGLUTIDE (PRR 49.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Liraglutide | 472 | 49.2 | 49.6 |
| Oral Semaglutide | 546 | 38.9 | 39.2 |
| Tranexamic Acid | 12 | 6.2 | 6.3 |
| Liothyronine Sodium | 10 | 5.3 | 5.3 |
| Theophylline | 13 | 5.2 | 5.2 |
| Orlistat | 29 | 5.2 | 5.2 |
| Telmisartan | 19 | 4.9 | 4.9 |
| Theophylline Anhydrous | 13 | 4.9 | 4.9 |
| Lurasidone Hydrochloride | 20 | 4.4 | 4.4 |
| Thyroid, Porcine | 10 | 4.3 | 4.3 |
| Levothyroxine Sodium | 250 | 3.8 | 3.8 |
| Sacubitril And Valsartan | 94 | 3.8 | 3.8 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 10 | 3.7 | 3.7 |
| Anastrozole | 29 | 3.7 | 3.7 |
| Levonorgestrel | 135 | 3.2 | 3.2 |
| Tirzepatide | 100 | 2.9 | 2.9 |
| Rucaparib | 5 | 2.6 | 2.6 |
| Relugolix | 13 | 2.6 | 2.6 |
| Desvenlafaxine Succinate | 14 | 2.4 | 2.4 |
| Ruxolitinib | 34 | 2.2 | 2.2 |
| Dofetilide | 5 | 2.2 | 2.2 |
| Etonogestrel | 18 | 1.7 | 1.7 |
| Medroxyprogesterone Acetate | 17 | 1.6 | 1.6 |
| Drospirenone And Ethinyl Estradiol | 15 | 1.6 | 1.6 |
| Diroximel Fumarate | 4 | 1.6 | 1.6 |
| Exenatide | 17 | 1.5 | 1.5 |
| Abaloparatide | 8 | 1.3 | 1.3 |
| Dulaglutide | 16 | 0.8 | 0.8 |
| Copper | 7 | 0.7 | 0.7 |
| Evolocumab | 24 | 0.7 | 0.7 |